The Insulin-PBM Rebate Kickback Scheme Appears to Coming to an End

Last year, on March 3, 2022, in what I believe was a fantastic accomplishment relatively early in Aaron Kowalski ' s tenure as CEO, the JDRF and Civica, Inc. (via the company ' s CivicaScript operating unit) jointly announced Civica ' s intention to commercialize biosimilars of the three bestselling insulin analogues at an affordable price of $30/vial or $55/box of five insulin pens. The Civica press release can be seen athttps://www.businesswire.com/news/home/20220303005321/en/Civica-to-Manufacture-and-Distribute-Affordable-Insulin/ and a concurrent press release from JDRF can be seen athttps://www.prnewswire.com/news-releases/jdrf-announces-support-of-civica-to-manufacture-and-distribute-low-cost-insulin-301495050.html. The plan is to introduce lower-priced biosimilars of the three bestselling insulin analogues now on the market (of Lantus, Novolog and Humalog, respectively), potentially as soon as 2024 (assuming they don ' t encounter unexpected regulatory delays). My followers may recall that not long after the Civica insulin announcement, I published an article on LinkedIn entitled " How the Civica Insulin Announcement May Be Disruptive to the PBM Kickback Scheme " (see the original athttps://www.linkedin.com/pulse/how-civica-insulin-announcement-may-disruptive-pbm-scheme-strumello/ for the article). It appears as if the predictions I made that the biggest loser from the Civica insulin announcement would not be pharma, rather the likely loser from the Civica insulin...
Source: Scott's Web Log - Category: Endocrinology Tags: Eli Lilly and Company 2023 Civica CivicaRx CivicaScript drug prices FTC insulin insulin prices JDRF Novo Nordisk Novo Nordisk Pharma Source Type: blogs